Sign in to confirm you’re not a bot
This helps protect our community. Learn more

SAR-bisPSMA - a next-generation radiopharmaceutical for prostate cancer diagnosis and treatment

Clarity Pharmaceuticals
267 subscribers
<__slot-el>
<__slot-el>
2.1K views 1 year ago
SAR-bisPSMA uniquely stands out from the current-generation PSMA-targeted radiopharmaceuticals in prostate cancer as it has two PSMA-targeting agents and uses the isotopes Cu-64 for diagnosis and Cu-67 for treatment. In a new video from Clarity, learn how the unique structure of SAR-bisPSMA translated into exciting initial pre-clinical data and is now mounting into promising clinical trial results that suggest SAR-bisPSMA may become the best-in-class PSMA-targeted agent for diagnosing and treating prostate cancer. ...more
...more
SAR-bisPSMA - a next-generation radiopharmaceutical for prostate cancer diagnosis and treatment
38Likes
2,175Views
2023Aug 21
SAR-bisPSMA uniquely stands out from the current-generation PSMA-targeted radiopharmaceuticals in prostate cancer as it has two PSMA-targeting agents and uses the isotopes Cu-64 for diagnosis and Cu-67 for treatment. In a new video from Clarity, learn how the unique structure of SAR-bisPSMA translated into exciting initial pre-clinical data and is now mounting into promising clinical trial results that suggest SAR-bisPSMA may become the best-in-class PSMA-targeted agent for diagnosing and treating prostate cancer.

Follow along using the transcript.

Clarity Pharmaceuticals

267 subscribers